Company Description
Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases.
The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins.
Its therapeutic candidate LCA-0061 degrades immunoglobulin E (IgE) for the treatment of allergic diseases, including food allergy.
The company also develops LCA-0062, a follow-on program designed to degrade IgE for the treatment of allergic diseases.
Additionally, it develops LCA-0321, a candidate designed to selectively degrade TSHR autoantibodies (thyrotropin receptor antibodies, or TRAbs), the pathogenic drivers of Graves' disease.
Lycia Therapeutics, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2019 |
| IPO Date | Oct 23, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Aetna Trombley |
Contact Details
Address: 400 East Jamie Court, Suite 200 South San Francisco, California 94080 United States | |
| Phone | (650) 392-3357 |
| Website | lyciatx.com |
Stock Details
| Ticker Symbol | LYCA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 1806540 |
| CUSIP Number | 55081P100 |
| ISIN Number | US55081P1003 |
| Employer ID | 84-3860514 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Aetna Wun Trombley, Ph.D. | President, Chief Executive Officer and Director |
| Amy Bachrodt | Chief Financial Officer |
| Chin Lee, M.D. | Chief Medical Officer |
| Steve Staben, Ph.D. | Chief Scientific Officer |
| Sofia Touami, Ph.D. | Chief Business Officer |
| William J. Rieflin | Chair and Director |
| Tim Anderson | Director |
| Ming Fang | Director |
| Laurent Fischer, M.D. | Director |
| Jane Pritchett Henderson | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | SCHEDULE 13G | Filing |
| Oct 26, 2026 | 8-K | Current Report |
| Oct 23, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 23, 2026 | 424B4 | Prospectus |
| Oct 22, 2026 | EFFECT | Notice of Effectiveness |
| Oct 22, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Oct 22, 2026 | CERT | Certification by an exchange approving securities for listing |
| Oct 20, 2026 | 8-A12B | Registration of securities |
| Oct 20, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Oct 5, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |